AI assistant
Cytosorbents Corp — Director's Dealing 2018
Sep 1, 2018
34501_dirs_2018-08-31_1150a181-5983-488d-ad69-62a22d179ef0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cytosorbents Corp (CTSO)
CIK: 0001175151
Period of Report: 2018-08-30
Reporting Person: Kraus Al (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-08-30 | Common Stock | M | 8000 | $2.10 | Acquired | 133046 | Direct |
| 2018-08-30 | Common Stock | M | 18000 | $4.20 | Acquired | 151046 | Direct |
| 2018-08-30 | Common Stock | S | 26000 | $14.4724 | Disposed | 125046 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-08-30 | Stock Option (right to buy) | $2.10 | M | 8000 | Disposed | 2019-01-08 | Common Stock (8000) | Direct |
| 2018-08-30 | Stock Option (right to buy) | $4.20 | M | 18000 | Disposed | 2019-01-28 | Common Stock (18000) | Direct |
Footnotes
F1: The stock options issued to the reporting person became exercisable according to the following vesting schedule: 4,500 stock options vested on 1/28/2009; 4,500 stock options vested on 1/28/2010; 4,500 stock options vested on 1/28/2011; and 4,500 stock options vested on 1/28/2012.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $14.605. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Includes (a) the following restricted stock units subject to vesting upon a "Change in Control" of CytoSorbents Corporation (the "Company"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (i) 3,300 restricted stock units granted on March 15, 2018, (ii) 6,000 restricted stock units granted on February 24, 2017, (iii) 5,000 restricted stock units granted on June 7, 2016, and (iv) 55,000 restricted stock units granted on April 8, 2015, and (b) 55,746 shares of common stock owned by the reporting person.